Skip to main content

Market Overview

Soliton Higher Following Preclinical Results For New Version Of Acoustic Pulse Device

Soliton Higher Following Preclinical Results For New Version Of Acoustic Pulse Device

Medical device company Soliton Inc. (NASDAQ: SOLY) shares are trading higher again after the company highlighted its preclinical results for its new RAP device, which "is a potentially important new way to treat cellulite and improve the appearance of the skin."

Why It's Important

Soliton claims its RAP technology has the ability to reduce cellulite and aid in tattoo removal, according to Soliton.

"While the proof-of-concept clinical trial results we have recently announced regarding the improvement in the appearance of cellulite have been very encouraging," said CEO Dr. Chris Capelli. "Understanding the basic science and biology behind these results is very important. We believe the discovery we are outlining here helps explain the promising results we saw from this trial, as well as setting the foundation for a platform technology that may have potential in a number of aesthetic indications."

Price Action

Soliton's stock traded higher by 15.6 percent to $17.51 per share at time of publication.

The Benzinga's quotes page shows Soliton has about 5 million shares in its float, which could make it a low-float play.

Related Links:

Soliton Rallies On FDA Approval For Tattoo Removal Device

Soliton Responds To Blog Calling It A 'PR Machine'


Related Articles (SOLY)

View Comments and Join the Discussion!

Posted-In: News Health Care Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at